Literature DB >> 6360019

In vitro and in vivo adherence of Candida albicans to mucosal surfaces.

N Lehrer, E Segal, L Barr-Nea.   

Abstract

In continuation of a previous study, chitin soluble extract (CSE) and anti-Candida albicans antibodies were found to inhibit the in vitro adherence of C. albicans to human vaginal epithelial cells by 60-70%. Pretreatment of epithelial cells with chitin, CSE or N-acetyl-glucosamine (NAG) decreased the percentage of adherence, while pretreatment of yeasts had no such effect, indicating that chitin or its derivatives may be involved in mediating the adherence of C. albicans. In vivo attachment of C. albicans to epithelial cells was studied in an experimental murine vaginitis created by inoculating mice intravaginally with yeasts at the oestrus stage. Attachment of the yeasts to exfoliated vaginal epithelial cells was followed microscopically, and the course of infection was assessed histopathologically in tissue sections at various times post-yeast inoculation. The infection rate at 24-h post-yeast inoculation was approximately 50%. Attempts were made to block in vivo attachment and prevent infection by pretreating 208 mice with either CSE, NAG, mannan or phosphate-buffered saline (PBS) prior to inoculation with yeasts. The infection rate among mice pretreated with mannan or PBS was 41.6% and 43.8%, respectively. Among CSE- or NAG-pretreated animals, the rate ranged from 0-9%. Treatment of mice with CSE or NAG after inoculation of the yeasts did not prevent infection. The data from the in vivo experiments reveal that pretreatment of animals with chitin derivatives blocks attachment of yeasts to the vaginal mucosal surfaces and leads to the prevention of vaginal infection in an experimental model.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360019     DOI: 10.1016/s0769-2609(83)80042-8

Source DB:  PubMed          Journal:  Ann Microbiol (Paris)        ISSN: 0300-5410


  17 in total

Review 1.  Adherence and receptor relationships of Candida albicans.

Authors:  R A Calderone; P C Braun
Journal:  Microbiol Rev       Date:  1991-03

2.  Identification of wall-specific antigens synthesized during germ tube formation by Candida albicans.

Authors:  M Casanova; M L Gil; L Cardeñoso; J P Martinez; R Sentandreu
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

3.  Variability in expression of cell surface antigens of Candida albicans during morphogenesis.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

4.  Fungispecificity of fluconazole against Candida albicans.

Authors:  R H Liss; R J Letourneau
Journal:  Mycopathologia       Date:  1989-12       Impact factor: 2.574

5.  Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome.

Authors:  D L Brawner; J E Cutler
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

7.  Hormonal factors in vaginal candidiasis in rats.

Authors:  O S Kinsman; A E Collard
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

8.  Analysis of cell wall extracts of Candida albicans by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot techniques.

Authors:  J Ponton; J M Jones
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

9.  Candidal vaginitis in hormone-treated mice: prevention by a chitin extract.

Authors:  E Segal; L Gottfried; N Lehrer
Journal:  Mycopathologia       Date:  1988-06       Impact factor: 2.574

10.  Ultrastructural and biochemical studies of two dynamically expressed cell surface determinants on Candida albicans.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.